---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020860"
form_type: "8-K"
ticker: "GERN"
cik: "0000886744"
company_name: "GERON CORP"
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T05:28:34.897271+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Geron posts Q1 net loss $38.1M; cash $409.2M; NDA on track for June 2023

## Summary
- Net loss of $38.1M ($0.07/sh) vs $30.1M loss ($0.09/sh) in Q1 2022; revenue negligible.
- Cash & marketable securities $409.2M; raised $213.3M from Jan 2023 offering plus $59.8M warrant exercises.
- Planned U.S. NDA submission for imetelstat in lower-risk MDS on track for June 2023; potential launch H1 2024.
- Reaffirmed FY2023 GAAP total expense guidance of $210M-$220M; non-GAAP $200M-$210M.
- Cash runway projected through Q3 2025, supporting US/EU launches and IMpactMF Phase 3 trial.

## SEC filing metadata
- accession: 0000950170-23-020860
- form_type: 8-K
- ticker: GERN
- cik: 0000886744
- company_name: GERON CORP
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886744/000095017023020860/0000950170-23-020860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886744/000095017023020860/gern-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020860
- JSON: https://secwatch.observer/filing/0000950170-23-020860.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020860.txt

## Key facts
- Earnings Releases
  GERON CORP reported the first quarter of 2023 results: revenue $21,000, net income $38.1 million, or $0.07 per share, EPS $0.07 per share. Guidance reaffirmed.
  - Period: the first quarter of 2023
  - Revenue: $21,000
  - Net income: $38.1 million, or $0.07 per share
  - EPS: $0.07 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: a net loss of $38.1 million, or $0.07 per share, compared to $30.1 million, or $0.09 per share, for the first quarter of 2022. Revenues for the first quarter of 2023 were $21,000 compared to $123,000 for the same period in 2022. Royalty revenues in 2023 and 2022 primarily reflect estimated royalties from sales of cell-based research products from the
  evidence_url: https://www.sec.gov/Archives/edgar/data/886744/000095017023020860/0000950170-23-020860-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.